ストックスクリーナーアプリを入手
68.39
1.00%
-0.69
アフターアワーズ：
69.40
1.01
+1.48%
前日終値:
$69.08
開ける：
$67.885
24時間の取引高:
402.50K
Relative Volume:
0.30
時価総額：
$7.25B
収益：
$628.56M
当期純損益:
$141.82M
株価収益率:
54.28
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-6.12%
1か月 パフォーマンス:
-7.93%
6か月 パフォーマンス:
+9.79%
1年 パフォーマンス:
+97.89%
1日の値動き範囲:
$67.77
$68.43
1週間の範囲:
$67.77
$73.78
52週間の値動き範囲:
$32.33
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
68.39 | 7.33B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance
What analysts say about Corcept Therapeutics Incorporated stockFree Stock Market Forecast Reports - jammulinksnews.com
What drives Corcept Therapeutics Incorporated stock priceRemarkable growth - jammulinksnews.com
Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Is Corcept Therapeutics Incorporated a good long term investmentTriple-digit wealth increases - Autocar Professional
Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - 富途牛牛
Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView
FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News
M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser
How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals
Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest
Corcept Therapeutics Submits New Drug Application to FDA - TipRanks
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN
Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada
Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada
Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com
Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail
10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey
Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance
Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener
Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga
Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada
Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada
Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK
Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia
Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News
Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive
Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga
Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha
Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus
Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):